DK2953971T3 - Il-11r-bindende proteiner og anvendelser deraf - Google Patents

Il-11r-bindende proteiner og anvendelser deraf Download PDF

Info

Publication number: DK2953971T3
Authority: DK; Denmark
Prior art keywords: binding proteins; proteins; binding
Prior art date: 2013-02-07

Application number

DK14749445.4T

Other languages

English (en)

Other versions

DK2953971T5 (da

Inventor

Kirsten Mae Edwards

Matthew Philip Hardy

Veronika Rayzman

Michael Wilson

Original Assignee

Csl Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-07

Filing date

2014-02-06

Publication date

2023-05-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51259368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2953971(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-02-07 Priority claimed from AU2013900389A external-priority patent/AU2013900389A0/en

2014-02-06 Application filed by Csl Ltd filed Critical Csl Ltd

2023-05-01 Application granted granted Critical

2023-05-01 Publication of DK2953971T3 publication Critical patent/DK2953971T3/da

2024-10-14 Publication of DK2953971T5 publication Critical patent/DK2953971T5/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Biotechnology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
Tropical Medicine & Parasitology (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)

DK14749445.4T 2013-02-07 2014-02-06 Il-11r-bindende proteiner og anvendelser deraf DK2953971T5 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AU2013900389A AU2013900389A0 (en)		2013-02-07	Il-11r binding proteins and uses thereof
US201361764756P	2013-02-14	2013-02-14
PCT/AU2014/000083 WO2014121325A1 (en)	2013-02-07	2014-02-06	Il-11r binding proteins and uses thereof

Publications (2)

Publication Number	Publication Date
DK2953971T3 true DK2953971T3 (da)	2023-05-01
DK2953971T5 DK2953971T5 (da)	2024-10-14

Family

ID=51259368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14749445.4T DK2953971T5 (da)	2013-02-07	2014-02-06	Il-11r-bindende proteiner og anvendelser deraf

Country Status (13)

Country	Link
US (2)	US9340618B2 (da)
EP (2)	EP4219552A3 (da)
JP (3)	JP6545105B2 (da)
KR (1)	KR102489953B1 (da)
CN (3)	CN104995211B (da)
AU (1)	AU2014214530B2 (da)
DK (1)	DK2953971T5 (da)
ES (1)	ES2942636T3 (da)
FI (1)	FI2953971T3 (da)
PL (1)	PL2953971T3 (da)
PT (1)	PT2953971T (da)
SG (1)	SG11201505762XA (da)
WO (1)	WO2014121325A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017049349A1 (en) *	2015-09-25	2017-03-30	Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research	A method of treatment and prophylaxis
GB201522186D0 (en) *	2015-12-16	2016-01-27	Singapore Health Services Pte Ltd And Nat University Of Singapore The	Treatment of fibrosis
CN109071613A (zh) *	2016-05-11	2018-12-21	通用电气医疗集团生物工艺研发股份公司	分离基质
GB201621439D0 (en)	2016-12-16	2017-02-01	Singapore Health Services Pte Ltd And Nat Univ Of Singapore	IL-11Ra Antibodies
AU2017378111A1 (en)	2016-12-16	2019-06-13	National University Of Singapore	IL-11 antibodies
GB201621431D0 (en)	2016-12-16	2017-02-01	Singapore Health Services Pte Ltd And Nat Univ Of Singapore The	Decoy cytokine receptor
GB201716733D0 (en)	2017-10-12	2017-11-29	Nat Univ Singapore	Treatment of SMC mediated disease
GB201809700D0 (en) *	2018-06-13	2018-08-01	Singapore Health Serv Pte Ltd	IL-11 antibodies
TWI858005B (zh)	2019-01-21	2024-10-11	新加坡商新加坡保健服務私人有限公司	肝毒性之治療
GB201902419D0 (en)	2019-02-22	2019-04-10	Singapore Health Serv Pte Ltd	Treatment of kidney injury
CN114364693A (zh)	2019-05-03	2022-04-15	新加坡保健服务私人有限公司	代谢性疾病的治疗和预防
GB201906291D0 (en)	2019-05-03	2019-06-19	Singapore Health Serv Pte Ltd	Treatment and prevention of metabolic diseases
GB202009292D0 (en)	2020-06-18	2020-08-05	Singapore Health Serv Pte Ltd	Treatment and prevention of disease caused by type IV collagen dysfunction
EP3939999A1 (en) *	2020-07-14	2022-01-19	Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
GB202017244D0 (en)	2020-10-30	2020-12-16	Nat Univ Singapore	Methods to extend health-span and treat age-related diseases
MX2023009946A (es)	2021-02-26	2023-09-04	Bayer Ag	Inhibidores de il-11 o il-11ra para uso en el tratamiento de sangrado uterino anormal.
US20250092126A1 (en)	2021-07-26	2025-03-20	Boehringer Ingelheim International Gmbh	Treatment and prevention of alcoholic liver disease
KR20240067079A (ko)	2021-08-30	2024-05-16	라센 테라퓨틱스 1, 인코포레이티드	항-IL-11Rα 항체
CN113735975B (zh) *	2021-09-07	2022-08-12	广东东阳光药业有限公司	一种抗il-11r抗体及其应用
US20250082608A1 (en)	2021-12-16	2025-03-13	Singapore Health Services Pte Ltd.	Treatment and prevention of glomerular disease
WO2024148240A1 (en) *	2023-01-06	2024-07-11	Lassen Therapeutics 1, Inc.	ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
PE20260306A1 (es)	2023-06-12	2026-02-11	Amgen Inc	Proteinas de union a receptor de linfotoxina beta agonistas

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196265A (en)	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4593089A (en)	1980-07-30	1986-06-03	Abbott Laboratories	Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en)	1985-07-22	1988-06-14	Abbott Laboratories	Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
DE4211351A1 (de)	1992-04-04	1993-10-07	Behringwerke Ag	Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
AU701578B2 (en)	1992-08-21	1999-02-04	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
SG41929A1 (en)	1992-09-25	1997-08-15	Commw Scient Ind Res Org	Target binding polypeptide
ES2275268T3 (es) *	1994-12-22	2007-06-01	Genetics Institute, Llc	Uso de un receptor de la interleuquina 11 humana.
US6274547B1 (en) *	1996-06-14	2001-08-14	Genetics Institute, Inc.	Methods comprising the use of human interleukin-11 receptor proteins
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
AUPO591797A0 (en)	1997-03-27	1997-04-24	Commonwealth Scientific And Industrial Research Organisation	High avidity polyvalent and polyspecific reagents
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
AU725609C (en)	1995-08-18	2002-01-03	Morphosys Ag	Protein/(poly)peptide libraries
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6541213B1 (en)	1996-03-29	2003-04-01	University Of Washington	Microscale diffusion immunoassay
ES2294799T3 (es)	1996-06-27	2008-04-01	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
CA2244326C (en)	1997-08-11	2006-03-28	Shinichi Eda	Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (es)	1998-04-20	2018-01-18	Roche Glycart Ag	Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
PT1308456E (pt)	1998-05-06	2007-12-03	Genentech Inc	Purificação de anticorpos por cromatografia de permuta iónica
US6562622B1 (en)	1998-05-08	2003-05-13	Diatech Pty, Ltd	Continuous in vitro evolution
CA2237915A1 (en) *	1998-05-19	1999-11-19	Stephen Shaughnessy	Osteoporosis treatment
WO2000034317A2 (en)	1998-12-08	2000-06-15	Biovation Limited	Method for reducing immunogenicity of proteins
WO2000042430A1 (en)	1999-01-15	2000-07-20	Medtox Scientific, Inc.	Lateral flow test strip
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
PT1355919E (pt)	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
US8178098B2 (en)	2001-04-03	2012-05-15	National Jewish Health	Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
AUPR544401A0 (en)	2001-06-04	2001-06-28	Bischof, Robert Juergen	Animal model for allergy
MXPA05000511A (es)	2001-07-12	2005-09-30	Jefferson Foote	Anticuepros super humanizados.
US7205159B2 (en)	2001-08-20	2007-04-17	Proteome Systems Intellectual Property Pty Ltd.	Diagnostic testing process and apparatus
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
JP2006507510A (ja)	2002-11-21	2006-03-02	インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング	組織低酸素症の体液マーカー
US20050014716A1 (en)	2003-05-21	2005-01-20	Wang Jin Wei	Pancreatic cancer treatment
AU2004245038A1 (en)	2003-06-02	2004-12-16	Alexion Pharmaceuticals, Inc.	De-immunized anti-CD3 antibody
WO2005014643A2 (en) *	2003-07-29	2005-02-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Il-11 muteins
ES2672640T3 (es)	2003-11-05	2018-06-15	Roche Glycart Ag	Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
AU2005250055B2 (en)	2004-06-02	2008-09-11	Adalta Pty Ltd	Binding moieties based on shark IgNAR domains
US8911726B2 (en)	2004-09-22	2014-12-16	Kyowa Hakko Kirin Co., Ltd	Stabilized human Igg4 antibodies
US20070135620A1 (en)	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
US20060263367A1 (en)	2005-05-23	2006-11-23	Fey Georg H	Bispecific antibody devoid of Fc region and method of treatment using same
KR20080068004A (ko)	2005-08-15	2008-07-22	아라나 테라퓨틱스 리미티드	뉴 월드 영장류 구조형성영역을 가진 조작 항체
CN101321538A (zh) *	2005-12-06	2008-12-10	惠氏公司	白细胞介素-11组合物和使用方法
EP1985305A1 (en)	2007-04-24	2008-10-29	Vivalis	Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en)	2007-05-21	2008-11-26	Vivalis	Recombinant protein production in avian EBx® cells
JP5330398B2 (ja) *	2007-10-26	2013-10-30	シーエスエル、リミテッド	サイトカインムテイン
US8182814B2 (en) *	2007-10-26	2012-05-22	Csl Limited	Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) *	2008-10-14	2013-08-27	Csl Limited	Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
AR074369A1 (es)	2008-11-20	2011-01-12	Genentech Inc	Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
EP2376109B1 (en)	2008-12-19	2019-01-23	MacroGenics, Inc.	Covalent diabodies and uses thereof
EP2389192A4 (en)	2009-01-23	2013-01-16	Biogen Idec Inc	STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
JP7536493B2 (ja) *	2020-04-08	2024-08-20	キヤノン株式会社	光学素子、光学機器、撮像装置

2014
- 2014-02-06 CN CN201480008007.6A patent/CN104995211B/zh active Active
- 2014-02-06 WO PCT/AU2014/000083 patent/WO2014121325A1/en not_active Ceased
- 2014-02-06 CN CN201910868161.5A patent/CN110551217B/zh active Active
- 2014-02-06 CN CN202311698495.5A patent/CN117843785A/zh active Pending
- 2014-02-06 KR KR1020157024292A patent/KR102489953B1/ko active Active
- 2014-02-06 FI FIEP14749445.4T patent/FI2953971T3/fi active
- 2014-02-06 AU AU2014214530A patent/AU2014214530B2/en active Active
- 2014-02-06 EP EP23158872.4A patent/EP4219552A3/en active Pending
- 2014-02-06 US US14/174,009 patent/US9340618B2/en active Active
- 2014-02-06 EP EP14749445.4A patent/EP2953971B1/en active Active
- 2014-02-06 JP JP2015556340A patent/JP6545105B2/ja active Active
- 2014-02-06 PL PL14749445.4T patent/PL2953971T3/pl unknown
- 2014-02-06 PT PT147494454T patent/PT2953971T/pt unknown
- 2014-02-06 ES ES14749445T patent/ES2942636T3/es active Active
- 2014-02-06 DK DK14749445.4T patent/DK2953971T5/da active
- 2014-02-06 SG SG11201505762XA patent/SG11201505762XA/en unknown
2015
- 2015-10-19 US US14/886,418 patent/US9796782B2/en active Active
2021
- 2021-10-07 JP JP2021165360A patent/JP7556838B2/ja active Active
2024
- 2024-09-12 JP JP2024158049A patent/JP2025000680A/ja active Pending

Also Published As

Publication number	Publication date
WO2014121325A1 (en)	2014-08-14
ES2942636T3 (es)	2023-06-05
FI2953971T3 (fi)	2023-04-27
KR20150115018A (ko)	2015-10-13
CN117843785A (zh)	2024-04-09
JP2025000680A (ja)	2025-01-07
CN110551217B (zh)	2023-12-15
CN110551217A (zh)	2019-12-10
KR102489953B1 (ko)	2023-01-20
CN104995211B (zh)	2019-09-13
DK2953971T5 (da)	2024-10-14
EP2953971A4 (en)	2016-10-12
EP2953971A1 (en)	2015-12-16
US9340618B2 (en)	2016-05-17
EP2953971B1 (en)	2023-03-01
US20140219919A1 (en)	2014-08-07
EP4219552A3 (en)	2023-09-13
SG11201505762XA (en)	2015-08-28
JP6545105B2 (ja)	2019-07-17
AU2014214530A1 (en)	2014-09-11
JP2022028651A (ja)	2022-02-16
PL2953971T3 (pl)	2023-07-03
JP7556838B2 (ja)	2024-09-26
EP4219552A2 (en)	2023-08-02
HK1217502A1 (en)	2017-01-13
US20160031999A1 (en)	2016-02-04
US9796782B2 (en)	2017-10-24
CA2898618A1 (en)	2014-08-14
JP2016515094A (ja)	2016-05-26
AU2014214530B2 (en)	2014-10-16
PT2953971T (pt)	2023-05-02
CN104995211A (zh)	2015-10-21

Publication	Publication Date	Title
IL290972A (en)	2022-05-01	Anti-vista antibodies and fragments
DK2953971T5 (da)	2024-10-14	Il-11r-bindende proteiner og anvendelser deraf
DK2970464T3 (da)	2020-08-03	Anti-lag-3-bindende proteiner
DK3683235T3 (da)	2024-07-08	Anti-IL-33-antistoffer og anvendelser deraf
DK3019533T3 (da)	2020-03-23	Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3027204T3 (da)	2022-04-19	Flerdelte signaleringsproteiner og anvendelser deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
IL246921B (en)	2019-09-26	Binding proteins and methods of use thereof
DK3581207T3 (da)	2023-02-06	Fusionsproteiner omfattende hoxd12 og nemo-bindingsdomæne og anvendelse deraf
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3027209T3 (da)	2020-11-02	Anti-Activin A-antistoffer og anvendelser deraf
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2951203T3 (da)	2019-08-12	Heterodimere proteiner
DK2812356T3 (da)	2019-07-08	CDIM-bindende proteiner og anvendelser deraf
DK3079719T3 (da)	2019-11-18	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
LT3041864T (lt)	2021-10-11	Il-18 surišantis baltymas (il-18p) uždegiminių ligų atvejais
DK3077467T3 (da)	2023-01-09	Sikkativsammensætning og anvendelse deraf
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK2968173T3 (da)	2020-12-21	Heterocykliske forbindelser og anvendelser deraf
HUE051357T2 (hu)	2021-03-01	IL-23 kötõ antitestek
DK3058936T3 (da)	2019-05-13	Peptidsammensætning og anvendelser deraf
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
DK3029038T3 (da)	2019-05-27	Tetrazolinonforbindelse og anvendelse deraf